Impact of Semaglutide on Tobacco Use and Related Health Behaviors

NCT06986993 · Recruiting

Last updated 2026-05-28

This clinical trial tests whether the medication semaglutide can help reduce tobacco use in adults who smoke cigarettes.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, double-blind study

Participants 40 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2024-07 · est. completion 2028-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06986993 ↗

Description as written by the study sponsor.

This pilot randomized trial will assess the impact of 12 weeks of semaglutide administration (vs placebo) on changes in: (i) tobacco use and related factors (nicotine craving, withdrawal, motivation to quit, etc.) and (ii) biological biomarkers of health (e.g., epigenetics, glucose variability via continuous glucose monitoring \[CGM\], etc.) in adult smokers with obesity (n = 40). We will integrate molecular biology procedures (e.g., epigenetics) to maximize internal validity with real-world smartphone-based ecological momentary assessment (EMA) surveys to maximize external validity

Treatments tested

Semaglutide also known as Ozempic Drug

Participants are randomized to receive either semaglutide or placebo (saline) via sc injection once a week for 12 weeks. Dose will be titrated per recommendations every 4 weeks,starting at .25mg, then 0.5mg and then 1.0mg
Placebo also known as Saline Drug

Participants are randomized to receive either semaglutide or placebo (saline) via sc injection once a week for 12 weeks. Dose will be titrated per recommendations every 4 weeks,starting at .25mg, then 0.5mg and then 1.0mg

Main thing measured	Cigarette smoking
Sponsor	University of Oklahoma
Conditions studied	Tobacco Use
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06986993 ↗